
James K. Mooney
Examiner (ID: 9373)
| Most Active Art Unit | 2655 |
| Art Unit(s) | 2654, 2655, 2695 |
| Total Applications | 772 |
| Issued Applications | 554 |
| Pending Applications | 72 |
| Abandoned Applications | 168 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 15083597
[patent_doc_number] => 20190336609
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-07
[patent_title] => C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors
[patent_app_type] => utility
[patent_app_number] => 16/398011
[patent_app_country] => US
[patent_app_date] => 2019-04-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 69530
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -44
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16398011
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/398011 | C40-, C28-, and C-32-Linked Rapamycin Analogs as mTOR Inhibitors | Apr 28, 2019 | Abandoned |
Array
(
[id] => 14715405
[patent_doc_number] => 20190248766
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-08-15
[patent_title] => ADDITIVE FOR IMPARTING ULTRAVIOLET ABSORBENCY AND/OR HIGH REFRACTIVE INDEX TO MATRIX, AND RESIN MEMBER USING SAME
[patent_app_type] => utility
[patent_app_number] => 16/394302
[patent_app_country] => US
[patent_app_date] => 2019-04-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 42808
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -32
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16394302
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/394302 | Additive for imparting ultraviolet absorbency and/or high refractive index to matrix, and resin member using same | Apr 24, 2019 | Issued |
Array
(
[id] => 16870031
[patent_doc_number] => 20210163498
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-03
[patent_title] => SOLID STATE FORMS OF LORLATINIB AND THEIR PREPARATION
[patent_app_type] => utility
[patent_app_number] => 17/047417
[patent_app_country] => US
[patent_app_date] => 2019-04-19
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14914
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17047417
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/047417 | SOLID STATE FORMS OF LORLATINIB AND THEIR PREPARATION | Apr 18, 2019 | Abandoned |
Array
(
[id] => 16711876
[patent_doc_number] => 20210079023
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-03-18
[patent_title] => PYRROLOBENZODIAZEPINES AND CONJUGATES THEREOF AS ANTITUMOUR AGENTS
[patent_app_type] => utility
[patent_app_number] => 17/046498
[patent_app_country] => US
[patent_app_date] => 2019-04-12
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 35118
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17046498
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/046498 | Pyrrolobenzodiazepines and conjugates thereof as antitumour agents | Apr 11, 2019 | Issued |
Array
(
[id] => 18013261
[patent_doc_number] => 11505543
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-11-22
[patent_title] => 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
[patent_app_type] => utility
[patent_app_number] => 17/042413
[patent_app_country] => US
[patent_app_date] => 2019-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 47062
[patent_no_of_claims] => 4
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 198
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17042413
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/042413 | 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication | Apr 10, 2019 | Issued |
Array
(
[id] => 15083607
[patent_doc_number] => 20190336614
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-11-07
[patent_title] => TARGETED PYRROLOBENZODIAZAPINE CONJUGATES
[patent_app_type] => utility
[patent_app_number] => 16/381448
[patent_app_country] => US
[patent_app_date] => 2019-04-11
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 36517
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16381448
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/381448 | Targeted pyrrolobenzodiazapine conjugates | Apr 10, 2019 | Issued |
Array
(
[id] => 16885347
[patent_doc_number] => 20210171542
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-10
[patent_title] => DI(HETERO)ARYL MACROCYCLIC COMPOUND FOR INHIBITING PROTEIN KINASE ACTIVITY
[patent_app_type] => utility
[patent_app_number] => 17/047877
[patent_app_country] => US
[patent_app_date] => 2019-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 30974
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17047877
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/047877 | Di(hetero)aryl macrocyclic compound for inhibiting protein kinase activity | Apr 9, 2019 | Issued |
Array
(
[id] => 17111719
[patent_doc_number] => 20210292316
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-23
[patent_title] => COMPOUNDS FOR THE TREATMENT OF CANCER
[patent_app_type] => utility
[patent_app_number] => 17/046245
[patent_app_country] => US
[patent_app_date] => 2019-04-10
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 41274
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -154
[patent_words_short_claim] => 19
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17046245
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/046245 | Compounds for the treatment of cancer | Apr 9, 2019 | Issued |
Array
(
[id] => 19027272
[patent_doc_number] => 11926619
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-12
[patent_title] => Certain pladienolide compounds and methods of use
[patent_app_type] => utility
[patent_app_number] => 17/045952
[patent_app_country] => US
[patent_app_date] => 2019-04-08
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 97337
[patent_no_of_claims] => 18
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 295
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17045952
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/045952 | Certain pladienolide compounds and methods of use | Apr 7, 2019 | Issued |
Array
(
[id] => 17815364
[patent_doc_number] => 11420962
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-08-23
[patent_title] => Indene derivatives useful in treating pain and inflammation
[patent_app_type] => utility
[patent_app_number] => 17/045626
[patent_app_country] => US
[patent_app_date] => 2019-04-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53317
[patent_no_of_claims] => 58
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 857
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17045626
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/045626 | Indene derivatives useful in treating pain and inflammation | Apr 4, 2019 | Issued |
Array
(
[id] => 15254057
[patent_doc_number] => 20190375762
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-12-12
[patent_title] => MK2 INHIBITORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/375317
[patent_app_country] => US
[patent_app_date] => 2019-04-04
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 57549
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -3
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16375317
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/375317 | MK2 inhibitors and uses thereof | Apr 3, 2019 | Issued |
Array
(
[id] => 18315083
[patent_doc_number] => 11629152
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-18
[patent_title] => Compound with anticancer activity
[patent_app_type] => utility
[patent_app_number] => 17/043348
[patent_app_country] => US
[patent_app_date] => 2019-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 91311
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 1389
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17043348
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/043348 | Compound with anticancer activity | Mar 28, 2019 | Issued |
Array
(
[id] => 18315083
[patent_doc_number] => 11629152
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-18
[patent_title] => Compound with anticancer activity
[patent_app_type] => utility
[patent_app_number] => 17/043348
[patent_app_country] => US
[patent_app_date] => 2019-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 91311
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 1389
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17043348
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/043348 | Compound with anticancer activity | Mar 28, 2019 | Issued |
Array
(
[id] => 18315083
[patent_doc_number] => 11629152
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-18
[patent_title] => Compound with anticancer activity
[patent_app_type] => utility
[patent_app_number] => 17/043348
[patent_app_country] => US
[patent_app_date] => 2019-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 91311
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 1389
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17043348
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/043348 | Compound with anticancer activity | Mar 28, 2019 | Issued |
Array
(
[id] => 18315083
[patent_doc_number] => 11629152
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-04-18
[patent_title] => Compound with anticancer activity
[patent_app_type] => utility
[patent_app_number] => 17/043348
[patent_app_country] => US
[patent_app_date] => 2019-03-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 91311
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 1389
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17043348
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/043348 | Compound with anticancer activity | Mar 28, 2019 | Issued |
Array
(
[id] => 18128843
[patent_doc_number] => 11555042
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-01-17
[patent_title] => Macrocyclic compounds as TRK kinases inhibitors
[patent_app_type] => utility
[patent_app_number] => 17/042385
[patent_app_country] => US
[patent_app_date] => 2019-03-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25910
[patent_no_of_claims] => 31
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 1737
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17042385
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/042385 | Macrocyclic compounds as TRK kinases inhibitors | Mar 26, 2019 | Issued |
Array
(
[id] => 14894017
[patent_doc_number] => 20190290774
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-26
[patent_title] => FOXC2 INHIBITOR AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/363335
[patent_app_country] => US
[patent_app_date] => 2019-03-25
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 25150
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -21
[patent_words_short_claim] => 12
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16363335
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/363335 | FOXC2 inhibitor and methods of use thereof | Mar 24, 2019 | Issued |
Array
(
[id] => 14893767
[patent_doc_number] => 20190290649
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2019-09-26
[patent_title] => SHP2 INHIBITORS AND USES THEREOF
[patent_app_type] => utility
[patent_app_number] => 16/356360
[patent_app_country] => US
[patent_app_date] => 2019-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 17674
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16356360
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/356360 | SHP2 inhibitors and uses thereof | Mar 17, 2019 | Issued |
Array
(
[id] => 16621451
[patent_doc_number] => 20210040104
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-02-11
[patent_title] => NOVEL KINASE INHIBITORS EXHIBITING ANTI-CANCER ACTIVITY AND THEIR METHOD OF USE
[patent_app_type] => utility
[patent_app_number] => 16/979602
[patent_app_country] => US
[patent_app_date] => 2019-03-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12713
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 160
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16979602
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/979602 | Kinase inhibitors exhibiting anti-cancer activity and their method of use | Mar 17, 2019 | Issued |
Array
(
[id] => 16991708
[patent_doc_number] => 20210230128
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-07-29
[patent_title] => ANTI-BLUE LIGHT COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/052198
[patent_app_country] => US
[patent_app_date] => 2019-03-13
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 7682
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -11
[patent_words_short_claim] => 177
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17052198
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/052198 | ANTI-BLUE LIGHT COMPOUND, PREPARATION METHOD AND APPLICATION THEREOF | Mar 12, 2019 | Abandoned |